Joseph Cadayona, NP
Family · Hinsdale, ILNPI 1750803490
Payments from drug & device makers
Across 118 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$507
- AbbVie$436
- Teva Pharmaceuticals USA, Inc.$275
- Novartis$218
- Argenx US, Inc.$159
- Genentech USA, Inc.$157
- plus $790 from 17 others
What the payments were for
- Food & beverage$2,543100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 22 | $507 |
| AbbVie | 22 | $436 |
| Teva Pharmaceuticals USA, Inc. | 10 | $275 |
| Novartis | 17 | $218 |
| Argenx US, Inc. | 7 | $159 |
| Genentech USA, Inc. | 6 | $157 |
| Banner Life Sciences, LLC | 6 | $125 |
| Acadia Pharmaceuticals Inc | 5 | $104 |
| Pfizer | 4 | $96 |
| Amgen | 3 | $72 |
| SK Life Science, Inc. | 2 | $61 |
| UCB, Inc. | 2 | $58 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Johnson & Johnson | 1 | $31 |
| Lundbeck LLC | 1 | $30 |
| Lilly USA, LLC | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Corium, LLC | 1 | $27 |
| Livanova USA, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
How this compares
$2,543 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 13 | $129,039 |
| Lacosamide | 84 | $18,941 |
| Emgality PenGalcanezumab-Gnlm | 21 | $14,891 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $9,219 |
| Pregabalin | 77 | $2,395 |
| Levetiracetam | 69 | $1,993 |
| Phenobarbital | 34 | $1,975 |
| Diazepam | 22 | $1,962 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $1,448 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 37 | $1,105 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 14 | $738 |
| Gabapentin | 46 | $737 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 25 | $701 |
| Clonazepam | 30 | $421 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $317 |
Paid to pharmacies, not to this prescriber.
Other family in Hinsdale
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.